Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23N3O7S |
Molecular Weight | 461.488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)OCC4=C(C)OC(=O)O4
InChI
InChIKey=ZKUKMWMSYCIYRD-ZXFNITATSA-N
InChI=1S/C21H23N3O7S/c1-10-12(31-20(28)30-10)9-29-19(27)15-21(2,3)32-18-14(17(26)24(15)18)23-16(25)13(22)11-7-5-4-6-8-11/h4-8,13-15,18H,9,22H2,1-3H3,(H,23,25)/t13-,14-,15+,18-/m1/s1
Molecular Formula | C21H23N3O7S |
Molecular Weight | 461.488 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4053214
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4053214
Lenampicillin is a prodrug of ampicillin that inhibits bacterial penicillin binding proteins (transpeptidase) and thus is effective against a wide range of bacterial infections. The drug was developed and marketed in Japan (Takacillin, Varacillin), however its current marketing status is unknown and supposed to be discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2683579 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TAKACILLIN Approved UseVarious infections including respiratory, urinary tract, skin and soft tissue, surgical, otolaryngological, ophthalmological and dental infections due to susceptible microorganism |
PubMed
Title | Date | PubMed |
---|---|---|
Non-mutagenicity of KBT-1585, a novel ester of ampicillin. | 1984 Feb |
|
Single- and multiple-dose pharmacokinetics of lenampicillin (KBT-1585) in healthy human subjects: comparative studies with amoxicillin. | 1985 Aug |
|
[Clinical evaluation of lenampicillin in the treatment of superficial suppurative skin and soft tissue infection. A double-blind study comparing amoxicillin]. | 1985 Jul |
|
[Metabolism of lenampicillin hydrochloride. I. Metabolism of ampicillin structure]. | 1985 Jul |
|
[Comparative study of the effectiveness of lenampicillin and bacampicillin on bacterial pneumonia by double blind method]. | 1985 Jun |
|
[Clinical studies on lenampicillin in the therapy of skin and soft tissue infections]. | 1985 Jun |
|
Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers. | 1986 May |
|
A comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin. | 1989 Jul |
|
Concentrations of ampicillin in human serum and mixed saliva following a single oral administration of lenampicillin, and relationship between serum and mixed saliva concentrations. | 1990 Mar |
|
High-performance liquid chromatographic assay of ampicillin and its prodrug lenampicillin. | 1990 May 16 |
|
Ampicillin concentrations in human oral tissues following a single oral administration of lenampicillin. | 1991 |
|
Differences in postoperative morbidity rates, including infection and dry socket, and differences in the healing process after mandibular third molar surgery in patients receiving 1-day or 3-day prophylaxis with lenampicillin. | 2002 Mar |
|
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. | 2010 Apr 16 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3906167
1,000 mg, in 4 equally divided doses
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:45:17 GMT 2023
by
admin
on
Sat Dec 16 17:45:17 GMT 2023
|
Record UNII |
8M568DM08K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5467
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
86273-18-9
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
DTXSID1057901
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106329
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
65646
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
C90912
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
100000082588
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
m6761
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
C045384
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
1553
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
SUB08430MIG
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
8M568DM08K
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY | |||
|
135748
Created by
admin on Sat Dec 16 17:45:17 GMT 2023 , Edited by admin on Sat Dec 16 17:45:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |